Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ProMIS Neurosciences Inc. - Common Shares (NQ: PMN )

1.150 -0.120 (-9.45%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 107,697
Open 1.260
Bid (Size) 1.120 (59)
Ask (Size) 1.160 (3)
Prev. Close 1.270
Today's Range 1.120 - 1.341
52wk Range 0.9200 - 3.100
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences And 2 Other Stocks Under $5 Executives Are Buying
Via Benzinga

Performance

YTD
-17.24%
-17.24%
1 Month
+3.60%
+3.60%
3 Month
-4.17%
-4.17%
6 Month
-43.90%
-43.90%
1 Year
-35.39%
-35.39%

More News

Read More
Why Exicure Shares Are Trading Higher By Around 180%; Here Are 20 Stocks Moving Premarket
Via Benzinga
ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Around $2M Bet On This Health Care Stock? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
Via Benzinga
PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q2 2024
Via InvestorPlace
ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
From ProMIS Neurosciences Inc.
Via GlobeNewswire
PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q1 2024
Via InvestorPlace
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
From ProMIS Neurosciences Inc.
Via GlobeNewswire
PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q4 2023
Via InvestorPlace
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.